Evidence map›Paper›PMID 33704722›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Single-Cell Analysis of BRAF

Joseph W Po, Yafeng Ma, Alison W S Luk, David Lynch, Bavanthi Balakrishnar, Daniel Brungs, Farhad Azimi, Adam Cooper, Erin Saricilar, Vinay Murthy and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Joseph W PoCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. joseph.po@health.nsw.gov.au.
Yafeng MaCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Alison W S LukCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
David LynchCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Bavanthi BalakrishnarLiverpool Hospital, Liverpool, NSW, Australia.
Daniel BrungsCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Farhad AzimiLiverpool Hospital, Liverpool, NSW, Australia.
Adam CooperCentre for Oncology Education and Research Translation (CONCERT), Liverpool, NSW, Australia.
Erin SaricilarSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Vinay MurthyCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Paul de SouzaCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Therese M BeckerCentre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia.
Ingham Institute · AUUNSW Sydney · AUWestern Sydney University · AULiverpool Hospital · AUCamden and Campbelltown Hospitals · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular testing of tumor biopsies allows for the identification of the key mutations driving a patient's cancer. However, this is limited to singular nodes and may not accurately reflect cancer heterogeneity. Circulating tumor cell (CTC) analyses offer a noninvasive method of interrogating the genomic profile of patient-derived tumor material. To date, molecular analysis of CTCs has relied on the characterization of bulk or pooled CTC lysates, limiting the detection of minor tumorigenic CTC subclones. Here, we show a workflow enabling BRAF

Indexed as

Mutation, MissenseNeoplastic Cells, CirculatingSingle-Cell AnalysisAmino Acid SubstitutionCell Line, TumorGTP PhosphohydrolasesHumansMelanomaMembrane ProteinsProto-Oncogene Proteins B-rafBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafCell linesCirculating tumor cells (CTC)Liquid biopsyMelanomaWhole-genome amplification (WGA)

Identifiers

PMID33704722
OpenAlexW3134059993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.